CD276 and acute myeloid leukemia: demonstrate an anti-B7-H3 CAR T-cell model that shows significant interferon-γ and IL-2 release with cytotoxicity against OCl-AML2, OCI-AML3, THP1, and U937 along with primary AML patient samples with E:T ratio of 1:5 after 48 hours (52).